PEMIVIBART
UNII 557S3L3FAP

Substance Identification & Data

This profile provides standardized clinical and technical data for Pemivibart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 557S3L3FAP.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2858673-18-2 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

557S3L3FAP

CAS Registry Number

2858673-18-2

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

PEMIVIBART

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

557S3L3FAP

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C203086

National Cancer Institute reference terminology for clinical and research data.

INN ID

13017

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

MN-184

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Pemivibart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

PEMIVIBART

Common Names & Synonyms

GAMMA1 HEAVY CHAIN HOMO SAPIENS (1-454) (VH (HOMO SAPIENS IGHV3-21*07 (88.8%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT (8.8.17) (26-33.51-58.97-113)) (1-124) -HOMO SAPIENS IGHG1*03, G1M3, NG1M1 CH1 R120, CH3 E12, M14, G1V78 L107, A114 (CH1 R120 (221) (125-222), HINGE 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365), M107>L (435), N114>A (441) (348-452), CHS (453-454)) (125-454)), (227-217')-DISULFIDE WITH LAMBDA2 LIGHT CHAIN HOMO SAPIENS (1'-218') (V-LAMBDA (HOMO SAPIENS IGLV1-40*01 (93.8%) -IGLJ1*01 (91.7%), CDR-IMGT (9.3.12) (26'-34'.52'-54'.91'-102')) (1'-112') -HOMO SAPIENS IGLC2*01 (100%) (113'-218')); DIMER (233-233'':236-236'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, GLYCOFORM ALFA

IMMUNOGLOBULIN G1 (435-LEUCINE,441-ALANINE), ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SPIKE GLYCOPROTEIN RECEPTOR-BINDING DOMAIN) (HUMAN MONOCLONAL VYD222 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VYD222 .LAMBDA.2-CHAIN, DIMER

IMMUNOGLOBULIN G1-LAMBDA2, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) PROTEIN, RECEPTOR BINDING DOMAIN (RBD)), HOMO SAPIENS MONOCLONAL ANTIBODY

IMMUNOGLOBULIN G1-LAMBDA2, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) PROTEIN, RECEPTOR BINDING DOMAIN (RBD)), HOMO SAPIENS MONOCLONAL ANTIBODY; GAMMA1 HEAVY CHAIN HOMO SAPIENS (1-454) (VH (HOMO SAPIENS IGHV3-21*07 (88.8%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT (8.8.17) (26-33.51-58.97-113)) (1-124) -HOMO SAPIENS IGHG1*03, G1M3, NG1M1 CH1 R120, CH3 E12, M14, G1V78 L107, A114 (CH1 R120 (221) (125-222), HINGE 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365), M107>L (435), N114>A (441) (348-452), CHS (453-454)) (125-454)), (227-217')-DISULFIDE WITH LAMBDA2 LIGHT CHAIN HOMO SAPIENS (1'-218') (VLAMBDA (HOMO SAPIENS IGLV1-40*01 (95.9%) -IGLJ1*01 (91.7%), CDR-IMGT (9.3.12) (26'-34'.52'-54'.91'-102')) (1'-112') -HOMO SAPIENS IGLC2*01 (100%) (113'-218')); DIMER (233-233'':236-236'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1, GLYCOFORM ALFA

PEMIVIBART [INN]

PEMIVIBART [USAN]

PEMIVIBART [WHO-DD]